Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 2Sarcoma 1Plasma cell 1Other hematologic neoplasm 1

Conditions

Multiple Myeloma 725Neoplasms, Plasma Cell 135Lymphoma, Non-Hodgkin 118Lymphoma 111Recurrence 103Leukemia, Lymphocytic, Chronic, B-Cell 99Precursor Cell Lymphoblastic Leukemia-Lymphoma 93Leukemia, Myeloid, Acute 92Hodgkin Disease 92Lymphoma, Large B-Cell, Diffuse 83Leukemia 75Lymphoma, Mantle-Cell 71Myelodysplastic Syndromes 70Lymphoma, Follicular 69Burkitt Lymphoma 60Lymphoma, B-Cell, Marginal Zone 59Neoplasms 54Lymphoma, Large-Cell, Immunoblastic 54Waldenstrom Macroglobulinemia 42Myeloproliferative Disorders 39Leukemia, Myelomonocytic, Chronic 39Leukemia, Myeloid, Chronic-Phase 39Primary Myelofibrosis 38Immunoglobulin Light-chain Amyloidosis 38Hematologic Neoplasms 38Lymphoma, T-Cell, Cutaneous 36Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 35Lymphoma, Large-Cell, Anaplastic 34Leukemia, Myeloid, Accelerated Phase 34Blast Crisis 33

Interventions

ibrutinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Multi-centric Castleman's Disease × Plasma cell × Clear all
NCT02109224 2015-08-20

Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection

National Cancer Institute (NCI)

Phase 1 Terminated
72 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Multi-centric Castleman's Disease, Burkitt Lymphoma, Leukemia, Hairy Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, HIV Infections, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Intraocular Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡